Related references
Note: Only part of the references are listed.Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Elie Ritch et al.
CLINICAL CANCER RESEARCH (2020)
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer
Elisa M. Ledet et al.
ONCOLOGIST (2020)
Circulating cell-free DNA: Translating prostate cancer genomics into clinical care
Delila Gasi Tandefelt et al.
MOLECULAR ASPECTS OF MEDICINE (2020)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Androgen receptor plasticity and its implications for prostate cancer therapy
Oliver Snow et al.
CANCER TREATMENT REVIEWS (2019)
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Qin Feng et al.
FRONTIERS IN ONCOLOGY (2019)
Towards precision oncology in advanced prostate cancer
Sheng-Yu Ku et al.
NATURE REVIEWS UROLOGY (2019)
Adaptive mutability of colorectal cancers in response to targeted therapies
Mariangela Russo et al.
SCIENCE (2019)
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer
Verena Sailer et al.
JCO PRECISION ONCOLOGY (2019)
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)
Hendrik Borgmann et al.
EUROPEAN UROLOGY (2018)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Nada Lallous et al.
GENOME BIOLOGY (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
The Androgen Receptor Gene Mutations Database: 2012 Update
Bruce Gottlieb et al.
HUMAN MUTATION (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor
CE Bohl et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Structural basis for antagonism and resistance of bicalutamide in prostate cancer
CE Bohl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
